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Abstract
Risks of radiation-induced second primary cancer following prostate 
radiotherapy using 3D-conformal radiotherapy (3D-CRT), intensity-modulated 
radiotherapy (IMRT), volumetric modulated arc therapy (VMAT), flattening 
filter free (FFF) and stereotactic ablative radiotherapy (SABR) were evaluated. 
Prostate plans were created using 10 MV 3D-CRT (78 Gy in 39 fractions) and 
6 MV 5-field IMRT (78 Gy in 39 fractions), VMAT (78 Gy in 39 fractions, with 
standard flattened and energy-matched FFF beams) and SABR (42.7 Gy in 
7 fractions with standard flattened and energy-matched FFF beams). Dose-
volume histograms from pelvic planning CT scans of three prostate patients, 
each planned using all 6 techniques, were used to calculate organ equivalent 
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doses (OED) and excess absolute risks (EAR) of second rectal and bladder 
cancers, and pelvic bone and soft tissue sarcomas, using mechanistic, bell-
shaped and plateau models. For organs distant to the treatment field, chamber 
measurements recorded in an anthropomorphic phantom were used to calculate 
OEDs and EARs using a linear model. Ratios of OED give relative radiation-
induced second cancer risks. 
SABR resulted in lower second cancer risks at all sites relative to 3D-CRT. 
FFF resulted in lower second cancer risks in out-of-field tissues relative to 
equivalent flattened techniques, with increasing impact in organs at greater 
distances from the field. For example, FFF reduced second cancer risk by up 
to 20% in the stomach and up to 56% in the brain, relative to the equivalent 
flattened technique. Relative to 10 MV 3D-CRT, 6 MV IMRT or VMAT with 
flattening filter increased second cancer risks in several out-of-field organs, by 
up to 26% and 55%, respectively. For all techniques, EARs were consistently 
low. The observed large relative differences between techniques, in absolute 
terms, were very low, highlighting the importance of considering absolute risks 
alongside the corresponding relative risks, since when absolute risks are very 
low, large relative risks become less meaningful.
A calculated relative radiation-induced second cancer risk benefit from 
SABR and FFF techniques was theoretically predicted, although absolute 
radiation-induced second cancer risks were low for all techniques, and 
absolute differences between techniques were small.
Keywords: prostate cancer, radiation-induced second primary cancer, 
stereotactic ablative radiotherapy (SABR), volumetric modulated arc therapy 
(VMAT), flattening filter free (FFF)
(Some figures may appear in colour only in the online journal)
1. Introduction
The development of a radiation-induced second primary cancer is an unwanted consequence 
of radiotherapy treatment. Theoretical concerns have been raised that modern techniques such 
as intensity-modulated radiotherapy (IMRT) may increase second cancer risk (Hall and Wuu 
2003). Owing to the relative newness of IMRT compared to the latency of second primary 
cancers, the clinical evidence regarding the impact of modern radiotherapy techniques on 
radiation-induced second cancer risk is too immature to determine if these concerns are war-
ranted (Huang et al 2011, Zelefsky et al 2012a, 2012b). While radiation-induced second can-
cer risk from IMRT has been compared to that from 3D-conformal radiotherapy (3D-CRT) in 
prostate planning studies (Followill et al 1997, Kry et al 2005a, 2005b, Stathakis et al 2007, 
Ruben et al 2008, Bednarz et al 2010), far fewer comparisons with other techniques such as 
volumetric modulated arc therapy (VMAT) (Rechner et al 2012), stereotactic ablative radio-
therapy (SABR) (Dasu et al 2011) and flattening filter free (FFF) techniques (Kry et al 2010, 
Halg et al 2012) have been performed.
This study aimed to compare radiation-induced second cancer risk from modern radio-
therapy techniques used to treat early prostate cancer. Conventionally fractionated schedules 
using 3D-CRT, IMRT and VMAT with standard (flattened) and FFF beams were evaluated, 
together with SABR using VMAT with standard and FFF beams.
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2. Methods
2.1. Contouring
Pelvic CT scans which were previously used for radiotherapy planning for three early stage 
prostate cancer patients were selected at random. On each of these, the, CTV was defined 
as the prostate alone, expanded 6 mm to PTV (compatible with daily online imaging using 
fiducial markers (Adamson et al 2011, Quon et al 2012, Beltran et al 2008). The rectum 
(recto-sigmoid junction to anus), bladder and femoral heads were contoured as organs-at-risk. 
A 5 mm shrink margin was created within the bladder and the subtraction of this from the 
whole bladder represented the bladder wall. Patients had empty rectums, thus the whole rectal 
volume represented rectal dose (since total rectal volume is considered a suitable surrogate for 
the rectal wall if the rectum is empty (Fiorino et al 2009)). All pelvic bones were contoured.
2.2. Planning
Five plans were produced for each pelvic CT using Monaco v3.3 (Elekta, AB Sweden) with a 
Monte Carlo algorithm, 6 MV photons, a 2 mm grid and the Agility head (Elekta, AB Sweden). 
A 5-field step and shoot IMRT plan was produced, prescribed 78 Gy in 39 fractions, with beams 
at 180°, 252°, 324°, 36° and 108°. Two VMAT plans prescribed 78 Gy in 39 fractions were 
produced using one 240° arc ( ° → °240 120 ), one with a 6 MV beam and one with an energy-
matched 6 MV FFF beam. Two SABR plans prescribing 42.7 Gy in 7 fractions were produced, 
using one 240° VMAT arc ( ° → °240 120 ), with 6 MV and energy-matched 6 MV FFF beams. 
‘Energy-matched’ means the FFF beam energy was re-tuned to match the relative dose in water 
at 10 cm deep for a 10  ×  10 cm standard 6 MV beam, 100 cm SSD (Paynter et al 2014). Doses 
were prescribed so that ≥95% of the PTV received ≥95% of the prescription dose and median 
dose was within 1 Gy of the prescription dose. Organ-at-risk constraints are described in table 1.
3D-CRT plans cannot be produced using Monaco v3.3.A 10 MV 3D-CRT four-field (0°, 
180°, 90°, 270°) 78 Gy in 39 fraction plan was therefore produced using Oncentra MasterPlan 
(Elekta, AB Sweden). Here, the prescription dose was normalized to the centre of the PTV and 
the 95% isodose covered the PTV (aiming for 100% coverage, accepting ≥95%).
2.3. In-field and close-to-field second cancer risk assessment
Differential dose-volume histograms (DVHs) using 0.01 Gy bin widths for rectum, bladder 
wall, pelvic bones and pelvic soft tissue (total scanned volume minus bones and prostate) 
were exported and used to calculate organ equivalent dose (OED) and excess absolute risk 
(EAR) for second rectal and bladder cancers, as well as bone and soft tissue sarcomas within 
the scanned volume, for all three pelvic CT scans and all six techniques, as described below. 
Average values are presented.
2.4. Out-of-field second cancer risk assessment
All six techniques from one of the three pelvic CT scans were delivered to the RANDO® phan-
tom (The Phantom Laboratory, USA) to assess out-of-field doses. Plans were delivered using 
a Synergy linac (Elekta, AB Sweden) with the Agility head (Elekta, AB Sweden) with and 
without FFF high dose rate mode. For conventionally fractionated treatments, three 2 Gy frac-
tions were delivered. For each SABR plan, one 6.1 Gy fraction was delivered. Measurements 
were performed in the midline at increasing distances from the isocentre by substituting each 
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relevant phantom slice for a 2.5 cm tall Perspex block with an ionization chamber holder, such 
that measurements were performed at approximately midline depth (figure 1). Doses at spe-
cific distances from the isocentre were taken to represent doses received by organs located at 
approximately those positions (table 2).
Out-of-field measurements were performed using a semi-flex ionization chamber (PTW 
GmbH, Germany), calibrated for 6 MV, 6 MV FFF and 10 MV beams. In other studies, ther-
moluminescent dosimeters (TLD) have often been used for out-of-field measurements given 
their relative energy independence. TLDs, however, can prove difficult in terms of accuracy 
and reproducibility, with uncertainties up to 10% quoted (Kragl et al 2011). The concern 
regarding chamber out-of-field measurements is the lower energy spectra in this region. It has 
been demonstrated, however, that the mean energy spectra out to 20 cm from the field edge are 
in the kilovoltage range (Kragl et al 2011), within the range of use of the chosen chamber. At 
10–20 cm from the field edge, it appears the energy spectra are plateauing or at worst decreas-
ing gradually (Kragl et al 2011), thus providing confidence in performing measurements at 
20 cm and beyond. In keeping with out-of-field chamber measurements performed by others, 
we assumed 5% uncertainty to account for potential inaccuracies resulting from the MV cali-
brated ion chamber and positioning inaccuracies (Kragl et al 2011). Readings were corrected 
for temperature, pressure and leakage. To estimate the impact of drift on measurements, on 
the first full day of measurements, we positioned a second semi-flex chamber at 70 cm from 
the isocentre and doses were recorded here at the same time as recording measurements at 
points closer to the isocentre (figure 1). At 70 cm, where the impact of drift was assumed to 
be greatest, the average standard deviation was 2.57% of the mean reading at 70 cm. Drift was 
therefore not considered likely to have a major impact on measured dose for the majority of 
readings, and would therefore be adequately encompassed within the 5% error assigned.
Table 1. Organ-at-risk constraints.
78 Gy in 39 fraction 
constraints Source SABR constraints Source
Rectum V70 Gy(90%) < 15%
V59 Gy(76%) < 35%
V51 Gy(65%) < 45%
HYPO-PR-RT 
trial (Franzen 
and Widmark 
2011)
V41.4 Gy(97%) < 3%
V38.4 Gy(90%) < 15%
V32.0 Gy(75%) ≤ 35%
V28.0 Gy(65%) ≤ 45%
V24.8 Gy(58%) < 70%
V19.6 Gy(46%) < 80%
HYPO-PC RT 
trial (Franzen and 
Widmark 2011) 
plus biologically 
equivalent 
constraints to 
74 Gy arm of 
CHHiP trial for 
high and low dose 
regions (Dearnaley 
2010)
Bladder V80 Gy(103%) < 15%
V75 Gy(96%) < 25%
V70 Gy(90%) < 35%
V65 Gy(83%) < 50%
RTOG 0126 
(Radiation 
Therapy 
Oncology 
Group 2014)
V41.4 Gy(97%) < 5%
V34.7 Gy(81%) < 25%
V29.9 Gy(70%) < 50%
Biologically 
equivalent 
constraints to 
74 Gy arm of 
CHHiP trial 
(Dearnaley 2010)
Femoral 
heads
Dmax ≤ 55 Gy(70%) HYPO-PR-RT 
trial (Franzen 
and Widmark 
2011)
Dmax ≤ 29.9 Gy(70%) HYPO-PC RT 
trial (Franzen and 
Widmark 2011)
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2.5. Assessment of head leakage and scatter
To assess out-of-field dose due to head scatter and leakage, out-of-field chamber measure-
ments were performed with the phantom pelvis (slices 30–35) removed, thus ensuring mea-
sured doses were predominantly from head scatter/leakage.
2.6. Second cancer risk evaluation
A variety of models exist for radiation-induced second cancer risk assessment, and the optimal 
is widely debated. Schneider’s concept of OED (Schneider et al 2005, 2011), which incor-
porates the impact of fractionation, was adopted. This concept states that two different dose 
distributions which result in the same second cancer risk have the same OED. For higher dose 
in-field and close-to-field regions, where the dose–response is not considered linear, the OED 
concept was used to calculate risks of rectal and bladder cancer using:
 (a) Schneider’s mechanistic model (Schneider 2009), which includes tissue specific repair/
repopulation constants,
 (b) a bell-shaped model (which suggests that risk increases in a linear fashion with dose up 
to a threshold before decreasing due to cell sterilization at higher doses without normal 
tissue repair (Schneider et al 2011), and
 (c) a plateau model (which suggests that risk increases initially in a linear fashion as dose 
increases up to a threshold at which risk levels off due to cell sterilization at higher doses 
with full normal tissue repair (Schneider et al 2011).
The risks of radiation-induced pelvic bone and soft tissue second malignancies were calcu-
lated using a specific mechanistic sarcoma model (Schneider 2009).
Figure 1. Experimental set-up for assessment of out-of-field dose. Perspex slice 
holding chamber was substituted for various slices in the RANDO® phantom (The 
phantom Laboratory, USA).
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For low dose out-of-field regions, where dose–response is considered linear, the OED con-
cept was used with a linear model.
The OED concept is discussed in detail elsewhere (Schneider et al 2005, 2011), but in 
summary:
∑=
V
VOED
1
RED
i
D D
T
i i
where VT is the total volume of the structure under consideration, VD is the volume of the dose 
bin i which receives dose Di and the REDDi is the risk equivalent dose for the dose bin receiv-
ing dose Di. RED is calculated according to
   =  (i) RED DD
when a linear model is applied (Schneider et al 2011), as is appropriate for low dose out-of-
field regions
and
⎜ ⎟⎛⎝
⎞
⎠α = − + − −
α
α α
−
′
− −
′
′
′
R
R R R(ii )RED
e
1 2 e (1 ) eD
D
D RR
D2 2 1
according to Schneider’s mechanistic model which incorporates R, a tissue specific repair/
repopulation parameter (Schneider et al 2011). The impact of fractionation here and in subse-
quent models is considered according to α′ (Schneider et al 2011):
α α β α β= + = +′ d D
D
d
T
T
where d is the dose per fraction, DT is the dose prescribed to the target and dT is the prescribed 
dose per fraction. Schneider et al fitted the parameters α and R for carcinoma induction using 
data from Atomic bomb survivors and patients treated with radiotherapy for Hodgkin disease 
(Schneider et al 2011). β is such that α/β = 3 Gy.
To illustrate the possible OED in the extreme scenarios of no repair/repopulation, and full 
repair/repopulation, RED and thus OED can also be calculated according to
α   = − ′D D(iii ) RED exp ( ) ,D
a bell-shaped model (R = 0) (Schneider et al 2011)
and
α
α
 = − −
′
′
D
(iv )RED
1 exp ( )
,D
a plateau model (R = 1) (Schneider et al 2011).
All of the above models approach a linear model at low doses (Schneider et al 2011).
When considering radiation-induced sarcoma, RED is calculated as (Schneider et al 2011)
⎜ ⎟⎛⎝
⎞
⎠α α= − + − − − ′
α
α α
−
′
− −
′
′
′
R
R R R RDRED
e
1 2 e (1 ) e .
D
D RR
D2 2 1
RED was also used to calculate the EAR of developing a radiation-induced second cancer 
in an organ with volume VT after exposure to dose RED at one age (agex) and after attaining 
a greater age (agea), according to (Schneider et al 2011)
∑ β μ= ⋅ ⋅ ⋅
V
VEARorg
1
RED (agex,agea)
T i
D Di i
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where β is the initial slope for the dose–response curve for radiation-induced second cancers, 
VD is the volume of the DVH bin receiving dose Di, REDDi is the RED for that bin and μ is a 
modifying factor which adjusts for age at exposure (agex) and attained age (agea), calculated 
according to (Schneider et al 2011)
μ γ γ  = −  +   ×  ( )(agex, agea) exp (agex 30) ln (agea / 70)e a
where γe and γa are age modifying factors and where β was originally defined for persons 
exposed at age 30 years and attaining age 70 years.
All EAR calculations in this study were performed for patients irradiated at age 60 years 
and attaining age 80 years. All parameters for second cancer risk calculation were taken from 
(Schneider et al 2011) and are shown in table 2.
Doses and risks presented are those for the whole treatment course.
3. Results
3.1. Plans
The number of monitor units (MU) required for all fractions in the delivered plans are shown 
in table 3.
3.2. In-field or close-to-field second cancer risks
Ratios of OED, thus relative risks of second rectal and bladder cancers and pelvic bone and 
soft tissue sarcoma for each technique relative to 3D-CRT, and averaged over the three evalu-
ated pelvic CT scans, are shown in figure 2.
SABR techniques, both FFF and flattened, resulted in the lowest OEDs for in-field and 
close-to-field tissues, and thus resulted in the greatest risk reductions relative to 3D-CRT, 
regardless of the model used.
Considering all alternative 78 Gy techniques relative to 3D-CRT, and all models, relative 
risks of rectal cancer, bladder cancer or soft tissue sarcoma were within 9%, 8% and 2% of 
that for 3D-CRT respectively. Risk of bone sarcoma was lower using all alternative techniques 
compared to 3D-CRT.
When comparing FFF with the equivalent flattened technique, for in-field and close-to-field 
tissues, there was minimal difference in risk (average relative risks for FFF consistently within 
2% of flattened techniques).
The EAR for in-field or close-to-field radiation-induced second cancer was low for all 
techniques and models (figure 3). Rectal and bladder cancer EARs ranged from 1.44–2.69 
Table 3. MUs required for delivery of whole treatment course for the six 
radiation techniques delivered to the RANDO phantom (all from one patient).
Technique Number of MUs for whole treatment course
SABR FFF 13 446
SABR 13 010
VMAT 78 Gy FFF 25 775
VMAT 78 Gy 24 040
IMRT 78 Gy 13 623
3D-CRT 78 Gy 10 429
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and 1.70–2.42 per 10 000 persons per year (PY) respectively using the mechanistic model. 
Within each model, absolute differences between techniques were low, at most 1.25 and 0.96 
per 10 000 PY for rectal and bladder cancer respectively. For each in-field or close-to-field site, 
absolute differences between models were also low, at most 1.09 per 10 000 PY for the rectum, 
and 0.66 per 10 000 PY for the bladder.
When comparing only 78 Gy techniques, absolute differences between techniques were 
small, at most 0.25 and 0.19 per 10 000 PY for rectal and bladder cancer respectively.
3.3. Out-of-field second cancer risks
Figure 4 shows radiation-induced second cancer risks relative to 3D-CRT (linear model).
As for in-field or close-to-field tissues, SABR resulted in reduced relative radiation-induced 
second cancer risks in out-of-field organs.
In contrast to in-field or close-to-field tissues, FFF in comparison to the equivalent flat-
tened technique, resulted in relative radiation-induced second cancer risk reductions in out-
of-field organs. The impact of FFF increased at greater distances from the treatment field. For 
example, in the region of the stomach, SABR FFF resulted in a 20% risk reduction relative to 
SABR, and VMAT 78 Gy FFF resulted in a 19% risk reduction relative to VMAT 78 Gy. In the 
region of the brain, both SABR FFF and VMAT 78 Gy FFF resulted in 56% risk reductions 
relative to equivalent flattened techniques.
In all out-of-field organs, IMRT resulted in increased radiation-induced second cancer risks 
relative to 3D-CRT, although increases were frequently small. At most, 26% risk increases 
were observed in the salivary gland and thyroid region using IMRT relative to 3D-CRT. 
Similarly, VMAT 78 Gy resulted in increased second cancer risks in most out-of-field organs 
of up to 55% relative to 3D-CRT. In contrast, VMAT 78 Gy FFF resulted in reduced second 
cancer risks relative to 3D-CRT of up to 32%.
EARs for second cancers in out-of-field organs were low for all sites and techniques 
(figure 5). At greater distances from the field, where the relative impact of FFF was greatest, 
in absolute terms, risks were very small. For example, in the region of the brain, the 56% 
risk reduction observed for FFF relative to the equivalent flattened technique, corresponded 
Figure 2. Relative risks of second malignancy in in-field or close-to-field tissues 
relative to 3D-CRT for whole treatment course. Error bars display the range of relative 
risks for the three pelvic CT scans used for planning.
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to absolute reductions from 0.0041 to 0.0018 per 10 000 PY for VMAT 78 Gy versus VMAT 
78 Gy FFF and 0.0024 to 0.0011 per 10 000 PY for SABR versus SABR FFF, thus highlighting 
the fact that when absolute risks are very low, large relative risks become less relevant.
In absolute terms, the increased risk from IMRT relative to 3D-CRT was also small: the 26% 
relative risk increase corresponded to an EAR increase from 0.0041 to 0.0051 per 10 000 PY 
for 3D-CRT versus IMRT for salivary gland cancer, and from 0.0009 to 0.0011 per 10 000 PY 
for thyroid cancer. Similarly the 55% risk increase from VMAT 78 Gy relative to 3D-CRT, 
amounted to absolute increases from 0.0027 to 0.0041 per 10 000 PY for cancers of the brain 
respectively. The 32% risk reduction observed with VMAT 78 Gy FFF relative to 3D-CRT was 
also small in absolute terms (0.0027 to 0.0018 per 10 000 PY for second brain cancers). Thus this 
data also illustrate that large relative risks become unhelpful when absolute risks are very low.
Combining all the out-of-field EARs, plus EARs for pelvic bone and soft tissue sarcoma, 
as well as the highest average EAR from each of the three models used for second rectal and 
Figure 3. EARs of second malignancy in in-field or close-to-field tissues for whole 
treatment course based on patients being irradiated aged 60 and attaining 80 years. Error 
bars display the range of relative risks for the three pelvic CT scans used for planning.
Figure 4. Relative risks of second malignancy in out-of-field tissues relative to 3D-CRT 
for whole treatment course. 5% error bars are shown to account for dosimetric and 
positioning uncertainty.
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bladder cancer estimation, the total EAR for a second cancer in any of the evaluated organs is 
shown for each technique in figure 6.
Thus SABR FFF resulted in the lowest ‘total’ second cancer risk (4.24 per 10 000 PY), and 
IMRT resulted in the highest ‘total’ second cancer risk (7.44 per 10 000 PY), thus the largest differ-
ence between techniques was low at 3.2 per 10 000 PY. The absolute differences between VMAT 
78 Gy FFF, VMAT 78 Gy, IMRT 78 Gy and 3D-CRT were very low, at most 0.62 per 10 000 PY.
3.4. Dose from head scatter and leakage
Out-of-field measurements performed following removal of the phantom pelvis demon-
strated that FFF resulted in reduced out-of-field doses due to head scatter/leakage compared 
to equivalent flattened techniques. The proportion of dose resulting from head leakage/scatter 
is shown in figure 7.
3.5. Components of dose and distance
Changes in total dose, head leakage/scatter and within patient scatter (total dose minus head 
leakage/scatter) with distance are shown in figure 8. A slight increase in dose from within 
patient scatter was observed with FFF compared to the equivalent flattened beam at 10 and 
15 cm from the isocentre, but this was outweighed by the reduction in dose due to reduced 
head leakage/scatter with FFF, resulting in lower total doses with FFF compared to the equiva-
lent flattened technique. Beyond 15 cm from the isocentre, within patient scatter was similar 
between FFF and the equivalent flattened techniques.
4. Discussion
We aimed to assess radiation-induced second cancer risk following modern, clinically rel-
evant prostate radiotherapy techniques. For all techniques, EARs were low. SABR conferred a 
consistently lower second cancer risk in all organs, while FFF conferred lower second cancer 
Figure 5. EARs of second malignancy in out-of-field organs (linear model) for whole 
treatment course based on patients being irradiated aged 60 and attaining 80 years. 5% 
error bars are shown to account for dosimetric and positioning uncertainty.
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risks in out-of-field organs, with the greatest relative impact at increasing distances from the 
field, where absolute benefits were small. The very low calculated absolute risks highlight the 
importance of not considering relative risks in isolation but also considering the associated 
absolute risks, as where absolute risks are very small, relative risks become far less important.
Prostate SABR delivers lower physical doses compared to conventionally fractionated 
treatments. Both lower physical doses and hypofractionation contributed to the observed sec-
ond cancer risk reductions. The rationale for hypofractionation resulting in reduced second 
cancer risk has been discussed elsewhere (Schneider et al 2010).
While other groups have also observed the relative impact of FFF on out-of-field doses 
in prostate cancer (Kry et al 2010, Halg et al 2012), we are unaware that others have quanti-
fied the size of the benefit or assessed risk in the setting of energy-matched FFF and stand-
ard (flattened) beams. As above, it is clinically relevant to consider relative risks alongside 
Figure 6. Summed EAR for all evaluated organs for all techniques based on patients 
being irradiated aged 60 and attaining 80 years.
Figure 7. Proportion of out-of-field dose resulting from head leakage and head scatter. 
3D-CRT: three-dimensional conformal radiotherapy, FFF: flattening filter free, 5% 
error bars are shown to account for dosimetric and positioning uncertainty.
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corresponding absolute risks, although it is acknowledged that calculation of EAR, as an 
extension of OED calculation, introduces additional uncertainties (i.e. the steepness of the ini-
tial portion of the dose–response curve and adjustment for the age of the population in ques-
tion). Despite this, calculated absolute benefits from FFF at large distances from the isocentre, 
were very small for this population. Irradiation of younger patients would result in greater 
absolute benefits from FFF. Most prostate cancer patients are, however, in the age range we 
considered, making calculated EARs relevant for the majority.
Kry et al (2010) evaluated non-energy matched FFF beams. An increase in total out-of-
field dose was observed 3–15 cm from the field edge which was attributed to lower energy 
FFF photons resulting in increased within patient scatter, potentially increasing second cancer 
risks (Kry et al 2010). Using energy-matched FFF beams, we observed no such increase in 
total out-of-field dose, and the slight increase in within patient scatter was outweighed by the 
substantial reduction in head leakage/scatter.
Few groups have evaluated radiation-induced second cancer risk in prostate cancer from 
SABR (Dasu et al 2011) and VMAT (Rechner et al 2012). Comparisons with data from other 
groups are difficult because of the different methods employed. In addition, whole body risk 
is often calculated rather than individual organ risks. The impact of linac based SABR tech-
niques on second malignancy risk has not been widely examined and we are aware of only 
one other group which has investigated this (Dasu et al 2011). Dasu et al quantified risks of 
second rectal and bladder cancer following 42.7 Gy in 7 fractions and 78 Gy in 39 fractions, 
both delivered using 3D-CRT (Dasu et al 2011). Exported DVHs were used to calculate risks 
using the competition model. Overall predicted risks were low, and CTV-PTV margin size 
had a larger impact on risk than fractionation schedule. The group concluded that the risks of 
second rectal and bladder cancers were similar between conventionally fractionated and ultra-
hypofractionated regimens (Dasu et al 2011). Thus the potential in-field benefits of SABR 
that we observed in this study were not observed in Dasu et al’s work. This likely reflects the 
differences in the modelling processes used: the competition model used predicts a maximum 
second cancer effect at around 4 Gy, while according to the OED model and accompanying 
parameters, risks may become maximal at higher doses (see below). In addition, while both 
models incorporate fractionation, fractionation is incorporated into each model differently. 
Figure 8. Changes in dose and components of dose with distance. 3D-CRT: three-
dimensional conformal radiotherapy, FFF: flattening filter free, VMAT: volumetric 
modulated arc therapy.
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Recalculating the risk of second bladder and rectal cancers for the three prostate patients 
using the competition model, and the same parameters as used by Dasu et al, we also observed 
broadly similar risks of second cancers between hypofractionated and all conventionally frac-
tionated techniques (table 4). Reaching a definitive conclusion about which of the two models 
is more accurate is difficult, if not impossible.
There is epidemiological evidence which suggests that following irradiation for pros-
tate cancer most second cancers arise in regions which receive doses greater than 5 Gy, thus 
including the rectum and bladder, and so adding support to Schneider’s model (Berrington de 
Gonzalez et al 2011). Similarly, data from patients irradiated for cervical cancer has suggested 
that there is an increasing dose–risk relationship for second rectal and bladder cancer for doses 
up to 60 Gy and greater (Boice et al 1988). In contrast, however, it has been demonstrated that 
the dose–risk relationship for second rectal and bladder cancers following irradiation for a 
variety of primary tumour sites is essentially flat from doses of 1 to 60 Gy (Suit et al 2007), 
and other work, also following irradiation of a variety of primary tumour sites, has demon-
strated that most second tumours arise at the edge of the PTV (Epstein et al 1997, Dorr and 
Herrmann 2002), which, in one of these studies, corresponded with regions receiving 6 Gy or 
less (Dorr and Herrmann 2002). No one model of radiation-induced carcinogenesis has ever 
been shown to be a perfect match for the epidemiological data, and epidemiological data, at 
times, appears conflicting. It is perhaps best, therefore, to view the differing results from the 
OED concept and competition model as illustrations of the uncertainties associated with the 
radiation-induced second cancer risk calculation process.
Few groups have evaluated radiation-induced second cancer risk in prostate cancer fol-
lowing VMAT compared to other external beam photon techniques. Rechner et al (2012) 
however, principally compared risks of bladder and rectal second cancer risks from VMAT 
with proton arc therapy. Excess relative risks were calculated and ratios of excess relative 
risks were used for comparisons (another modelling process which incorporates the effects 
of fractionation and reports risk relative to that in an non-irradiated population (Sachs and 
Brenner 2005, Shuryak et al 2009a, 2009b)). DVH data provided details of the therapeu-
tic dose for VMAT and were also used to estimate secondary radiation doses (i.e. dose 
resulting from head leakage and scatter and additional within patient scatter). Monte Carlo 
simulations and previously published data were used to estimate secondary radiation doses 
resulting from proton arc therapy. Proton arc therapy predicted significantly lower risks of 
second bladder or rectal cancer according to linear-exponential and linear-plateau models 
compared to VMAT, while there was no significant difference in second rectal or bladder 
cancer risk when using the linear model. The group also compared calculated excess relative 
risks of second bladder and rectal from VMAT with that previously estimated for IMRT by 
Table 4. Predicted percentage risks (%) of second rectal and bladder cancers 
based on competition model averaged for three pelvic CT scans
Rectum Bladder
Average Range Average Range
SABR FFF 0.57 0.55–0.59 0.22 0.20–0.25
SABR 0.58 0.55–0.61 0.22 0.20–0.25
VMAT 78 Gy FFF 0.58 0.54–0.64 0.25 0.24–0.26
VMAT 78 Gy 0.58 0.55–0.63 0.25 0.24–0.26
IMRT 78 Gy 0.54 0.51–0.61 0.27 0.24–0.29
3D-CRT 78 Gy 0.47 0.43–0.55 0.25 0.22–0.27
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another group (Fontenot et al 2009). Numerically, VMAT resulted in lower risks of second 
bladder and rectal cancer compared to IMRT (excess relative risk for bladder cancer: 5.25 
with VMAT and 8.88 with IMRT, excess relative risk for rectal cancer: 2.09 with VMAT and 
3.32 for IMRT) (Rechner et al 2012). These risks, however, were calculated using a linear 
model, which is often considered inappropriate in higher dose regions (Hall and Wuu 2003, 
Ruben et al 2008). The use of a different model may also explain why greater differences 
were observed between IMRT and VMAT by Rechner et al and were greater than what was 
observed in this current piece of work.
Theoretical concerns have been raised regarding a potential large increase in second cancer 
risk using IMRT compared to 3D-CRT (Followill et al 1997, Hall and Wuu 2003, Kry et al 
2005a, 2007, Stathakis et al 2007). Recent papers have suggested that any increased risk from 
6 MV IMRT would be very small, particularly when compared to higher energy 3D-CRT (as 
often employed clinically) (Ruben et al 2008, 2011, Bednarz et al 2010, Ardenfors et al 2014). 
The theoretical risk increase is often attributed to two things: increased MU requirements 
for IMRT, resulting in increased head leakage, thus contributing to out-of-field dose, and the 
change in dose distribution, resulting in an increased volume of normal tissue receiving low 
doses. We observed increased risks from 6 MV IMRT and VMAT 78 Gy relative to 10 MV 
3D-CRT in out-of-field organs of up to 26% and 55% respectively, likely because of increased 
MU. In absolute terms, however, where the greatest relative risk increases occurred, absolute 
increases were very small. VMAT 78 Gy FFF, however, resulted in reduced risks relative to 
3D-CRT, although, again, absolute differences in risk were low. When considering individual 
in-field or close-to-field tissues, the impact of a change in dose distribution when moving 
from 3D-CRT to IMRT did not translate into clinically relevant increases in second cancer 
risk according to the models employed here. This can be explained through inspection of the 
DVHs for in-field and close-to-field organs. DVHs for all 78 Gy treatments for one pelvic CT 
are plotted in figures 9(a)–(d). The relationship between dose and risk equivalent dose (RED) 
according to Schneider’s models has also been superimposed onto the DVH curves (Schneider 
et al 2011). Note that the values for RED are not shown, but the dose–RED curves are plotted 
purely to illustrate the shape of the dose–risk relationship.
Visual inspection of differential DVHs for the rectum for all 78 Gy treatments (figure 8(a)) 
are not suggestive that the rectum receives a greater proportion of low dose irradiation with 
IMRT, and dose distributions are largely similar between 3D-CRT and IMRT until around 
40 Gy where there is a peak in the 3D-CRT DVH. For IMRT a smaller peak is seen around 
48 Gy. In Schneider’s model for rectal cancer induction, and based on the fractionation used 
here (i.e. 39 fractions), the risk peaks at about 23 Gy according to the bell-shaped model, 
and at about 35 Gy according to the mechanistic and plateau models. The 40–50 Gy region 
is therefore in the region of decreasing risk and the 48 Gy peak in the IMRT DVH falls in 
a lower risk portion of the curve compared to the 40 Gy peak for the 3D-CRT curve, and 
this may contribute to the slightly reduced risk observed in the risk of rectal cancer using 
IMRT relative to 3D-CRT (although in absolute terms the difference in risk is very small). 
Considering the VMAT treatments, a higher proportion of rectal tissue receives doses in the 
15 to 25 Gy range compared to IMRT and 3D-CRT. This dose region falls in the highest risk 
portion of the bell-shaped model, thus resulting in the slightly increased risk of rectal cancer 
using VMAT relative to 3D-CRT and IMRT using this model. Considering the competition 
model, which predicts maximum effect at around 4 Gy, IMRT and VMAT treatments display a 
slightly higher volume of tissue receiving doses in the 3–4 Gy region, resulting in the slightly 
higher risks seen with IMRT and VMAT according to this model (table 4).
In the case of the bladder DVHs (figure 8(b)), IMRT appears to result in a slight increase 
in the volume of tissue receiving 2–5 Gy, which encompasses the area of maximal effect 
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Figure 9. (a) Differential DVHs comparing 78 Gy techniques: rectum; RED: risk 
equivalent dose. (b) Differential DVHs comparing 78 Gy techniques: bladder (only first 
10.5 Gy shown to allow differences to be more clearly observed); RED: risk equivalent 
dose. (c) Differential DVHs comparing 78 Gy techniques: pelvic bones; RED: risk 
equivalent dose. (d) Differential DVHs comparing 78 Gy techniques: pelvic soft tissues; 
RED: risk equivalent dose.
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according to Schneider’s bladders models, thus resulting in the slightly higher relative risk 
of second bladder cancers from IMRT compared to 3D-CRT. For both VMAT treatments, a 
smaller volume of tissue receives doses in the region of 1–2 Gy compared to 3D-CRT, and 
similar volumes of tissues receive doses of 3–5 Gy compared to 3D-CRT, thus resulting in 
only very slight second bladder cancer risk reductions using VMAT. These differences in dose 
distributions between techniques also explain the slight increase in second bladder cancer 
risk observed using IMRT compared to 3D-CRT, and similarities in risk between VMAT and 
3D-CRT, according to the competition model.
Considering the pelvic bone DVHs (figure 8(c)), VMAT results in a larger volume of tis-
sue receiving very low doses (<1 Gy) and IMRT results in a slight increased volume of tissue 
receiving doses around 2 Gy and around 6–10 Gy compared to 3D-CRT. Schneider’s model, 
however, predicts a peak in bone sarcoma risk at around 54 Gy. A peak in dose is seen for the 
3D-CRT plan at just above 40 Gy, thus falling in the higher risk region of the dose–RED curve, 
and contributing to the increased relative risk of second bone sarcoma observed for 3D-CRT 
compared to all other techniques, while the increased volume of bone receiving lower doses 
from IMRT and VMAT fall on a much lower risk part of the dose–risk curve, and thus have 
little impact on the calculated risk.
In terms of the soft tissue DVHs (figure 8(d)), where perhaps one might expect to see 
the biggest impact of an increased volume of tissue receiving a lower dose of radiation with 
IMRT or VMAT techniques, it can be seen that VMAT, as with the pelvic bone DVHs, results 
in a higher volume of tissues receiving very low doses (i.e. <1 Gy), while 3D-CRT results in 
a slightly larger volume of tissue receiving 2–3 Gy. Schneider’s model predicts maximum 
effect at around 58 Gy and so it is doses in this region which will have the largest impact on 
risk. In the 50–60 Gy region, the DVH is largely similar for all techniques, and there is only 
a very slight peak at about 42 Gy for 3D-CRT. Overall, therefore, calculated risks for pelvic 
soft tissue sarcoma are similar for all four techniques, and the traditional concern that IMRT/
VMAT techniques result in a larger volume of normal tissue receiving lower (and thus more 
cancer inducing) doses appears to contribute little to the overall calculated risk, according to 
the model used here.
The rectal, bladder, pelvic bone and pelvic soft tissue DVHs for the SABR FFF and stand-
ard (flattened) plans were very similar (data not shown), thus explaining the similar second 
cancer risks estimations for these two techniques, regardless of whether the OED concept or 
competition model was used.
There are a number of limitations in our work. Firstly, as alluded to above, there are uncer-
tainties in radiation-induced second cancer models and parameters. Schneider’s concept of 
OED was employed as this incorporates fractionation and, with the mechanistic model, includes 
repair and repopulation (Schneider et al 2011). Models based on full and no repair/repopula-
tion, were also adopted to illustrate a range of possibilities. All models suggested benefit from 
SABR in in-field or close-to-field tissues, which is where the majority of radiation-induced 
second cancers arise (Epstein et al 1997, Dorr and Herrmann 2002, Berrington de Gonzalez 
et al 2011). Similarly, all models predicted broadly comparable second rectal and bladder 
cancer risks from 3D-CRT, 5-field IMRT and VMAT 78 Gy (FFF or standard).
Secondly, the appropriateness of these linear-quadratic (LQ) based models for high dose 
per fraction treatments could be questioned (Brenner 2008, Kirkpatrick et al 2008). Our 
SABR prescription dose was 6.1 Gy per fraction, and, most normal tissues received doses far 
below the prescription dose. Where concern about high dose per fraction treatments and the 
LQ model have been raised, this is usually in the setting of radiosurgical doses (e.g. >10 Gy 
per fraction) (Kirkpatrick et al 2008). Thus the doses considered in this current study were 
within the range in which the LQ model is considered reliable.
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Thirdly, we did not assess the impact of neutron contamination on second cancer risks for 
the 10 MV plan. It has previously been demonstrated, however, that at 10 MV this effect is 
very small (Kry et al 2005a). Fourthly, only three patients’ pelvic CT scans were evaluated 
for in-field and close-to-field second cancer risks, and only one was evaluated for out-of-field 
risks. Similar to this study, the majority of prostate cancer planning studies which evaluate 
radiation-induced second cancer risks in a series of adult patients, all planned using the same 
variety of techniques, do so in one to three patients. The reason for the small sample size is 
that the primary interest is differences between techniques rather than inter-patient variabil-
ity (Kry et al 2005b, 2010, Schneider 2006, Stathakis et al 2007, Ruben et al 2008, Fontenot 
et al 2009, Bednarz et al 2010, Kragl et al 2011, Blais et al 2012, Rechner et al 2012) A few 
studies have, however, compared up to 10 patients, each planned using the same variety of 
techniques (Fontenot et al 2010, Patil et al 2010, Yoon et al 2010). Dasu et al (2011), how-
ever, aimed to evaluate inter-patient variability in second cancer risk and so included 100 
patients, each planned using SABR and conventionally fractionated radiotherapy, although 
this analysis was restricted to rectal and bladder DVH analysis, and did not include out-of-
field dose measurements. Given the relative anatomical constancy of the prostate in relation 
to organs-at-risk, however, any variability in second cancer risk is likely to be less than what 
might be expected for tumours with greater variability in location, suggesting that a low 
number of patients may be acceptable. This is reinforced by the consistency in results for 
the three evaluated patients, thus adding confidence to our use of a small patient sample. For 
out-of-field organs, minimal variation in dose between patients would be expected, and so 
the use of one patient, planned in several different ways, is adequate for comparison of dif-
ferent techniques.
We did not include the impact of image-guided radiotherapy (IGRT) on second can-
cer risk as this will vary with the IGRT technique employed. The CTV–PTV margin was 
intended for daily online IGRT with fiducial markers. Thus conventionally fractionated 
regimens will require at least 39 images while SABR will require at least 7 images. If auto-
matic couch adjustments are used, and treatment is sufficiently rapid, then further imaging 
following shifts or post-treatment would be unnecessary. The need for fewer images with 
ultra-hypofractionated regimens potentially adds additional second cancer benefit to SABR 
techniques.
Different hardware and software combinations as well as treatment margins may all con-
tribute to differences in second cancer risk (Ruben et al 2008, Dasu et al 2011). We attempted 
to minimize these as far as possible by delivering all plans on the same machine, by creating 
plans using the same planning system as far as possible, and by using the same CTV–PTV 
margin. Differences in risks observed in this study should therefore largely be due to the 
doses, fractionations and planning techniques under evaluation. Our findings are, however, 
specific for the planning and delivery systems adopted here.
5. Conclusion
In summary, we compared radiation-induced second cancer risks following contemporary 
clinically relevant radiotherapy techniques for early prostate cancer. SABR resulted in reduced 
relative second cancer risks in all organs, while FFF resulted in reduced second cancer risks in 
out-of-field organs relative to equivalent flattened techniques, particularly at greater distances 
from the treatment field. Although large differences in relative risk were sometimes observed, 
in absolute terms, second cancer risks were low, emphasizing the importance of considering 
absolute risks in addition to the comparison of relative risks. Until clinical data regarding 
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radiation-induced second cancers in irradiated prostate patients treated with contemporary 
techniques matures, data from this and other planning studies should be considered when 
selecting appropriate radiation techniques for individual patients.
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